Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
Kreuzberger N, Hirsch C, Andreas M, Böhm L, Bröckelmann PJ, Di Cristanziano V, Golinski M, Hausinger RI, Mellinghoff S, Lange B, Lischetzki T, Kappler V, Mikolajewska A, Monsef I, Park YS, Piechotta V, Schmaderer C, Stegemann M, Vanshylla K, Weber F, Weibel S, Stephani C, Skoetz N. Kreuzberger N, et al. Among authors: brockelmann pj. Cochrane Database Syst Rev. 2022 Aug 9;8(8):CD015021. doi: 10.1002/14651858.CD015021. Cochrane Database Syst Rev. 2022. PMID: 35943061 Free PMC article. Review.
Hodgkin Lymphoma in Adults.
Bröckelmann PJ, Eichenauer DA, Jakob T, Follmann M, Engert A, Skoetz N. Bröckelmann PJ, et al. Dtsch Arztebl Int. 2018 Aug 6;115(31-32):535-540. doi: 10.3238/arztebl.2018.0535. Dtsch Arztebl Int. 2018. PMID: 30149835 Free PMC article.
Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19.
Mellinghoff SC, Vanshylla K, Dahlke C, Addo MM, Cornely OA, Klein F, Persigehl T, Rybniker J, Gruell H, Bröckelmann PJ. Mellinghoff SC, et al. Among authors: brockelmann pj. Front Immunol. 2021 Dec 20;12:798276. doi: 10.3389/fimmu.2021.798276. eCollection 2021. Front Immunol. 2021. PMID: 34987520 Free PMC article.
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review.
Piechotta V, Mellinghoff SC, Hirsch C, Brinkmann A, Iannizzi C, Kreuzberger N, Adams A, Monsef I, Stemler J, Cornely OA, Bröckelmann PJ, Skoetz N. Piechotta V, et al. Among authors: brockelmann pj. Blood Cancer J. 2022 May 31;12(5):86. doi: 10.1038/s41408-022-00684-8. Blood Cancer J. 2022. PMID: 35641489 Free PMC article.
Toxicities of novel therapies for hematologic malignancies.
Simon F, Garcia Borrega J, Bröckelmann PJ. Simon F, et al. Among authors: brockelmann pj. Expert Rev Hematol. 2020 Mar;13(3):241-257. doi: 10.1080/17474086.2020.1728249. Epub 2020 Feb 17. Expert Rev Hematol. 2020. PMID: 32037909 Review.
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Bröckelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, Sasse S, Sökler M, Kerkhoff A, Mathas S, Hüttmann A, Bormann M, Zimmermann A, Mettler J, Fuchs M, von Tresckow B, Baues C, Rosenwald A, Klapper W, Kobe C, Borchmann P, Engert A. Bröckelmann PJ, et al. JAMA Oncol. 2020 Jun 1;6(6):872-880. doi: 10.1001/jamaoncol.2020.0750. JAMA Oncol. 2020. PMID: 32352505 Free PMC article. Clinical Trial.
Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial.
Voltin CA, Mettler J, van Heek L, Goergen H, Müller H, Baues C, Keller U, Meissner J, Trautmann-Grill K, Kerkhoff A, Fuchs M, Sasse S, von Tresckow B, Dietlein M, Borchmann P, Engert A, Kobe C, Bröckelmann PJ. Voltin CA, et al. Among authors: brockelmann pj. Clin Cancer Res. 2021 Jan 15;27(2):402-407. doi: 10.1158/1078-0432.CCR-20-3303. Epub 2020 Oct 29. Clin Cancer Res. 2021. PMID: 33122344 Clinical Trial.
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B. Bröckelmann PJ, et al. J Clin Oncol. 2023 Feb 20;41(6):1193-1199. doi: 10.1200/JCO.22.02355. Epub 2022 Dec 12. J Clin Oncol. 2023. PMID: 36508302 Clinical Trial.
Hematological immune related adverse events after treatment with immune checkpoint inhibitors.
Kramer R, Zaremba A, Moreira A, Ugurel S, Johnson DB, Hassel JC, Salzmann M, Gesierich A, Weppler A, Spain L, Loquai C, Dudda M, Pföhler C, Hepner A, Long GV, Menzies AM, Carlino MS, Sachse MM, Lebbé C, Baroudjian B, Enokida T, Tahara M, Schlaak M, Hayani K, Bröckelmann PJ, Meier F, Reinhardt L, Friedlander P, Eigentler T, Kähler KC, Berking C, Zimmer L, Heinzerling L. Kramer R, et al. Among authors: brockelmann pj. Eur J Cancer. 2021 Apr;147:170-181. doi: 10.1016/j.ejca.2021.01.013. Epub 2021 Mar 9. Eur J Cancer. 2021. PMID: 33706206
79 results